{"entity":{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","aka":[],"tldr":"A phase 1/2 trial of Anvumetostat and Docetaxel in advanced solid tumours, run by Amgen, active and no longer recruiting.","summary":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) is a phase 1/2 interventional study registered as NCT05094336 by Amgen, with 329 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Anvumetostat, Docetaxel and Comparator Anvumetostat Test Tablet.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05094336","url":"https://clinicaltrials.gov/study/NCT05094336"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["anvumetostat","docetaxel"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05094336","phase":"1/2","setting":"A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors","sponsor":"Amgen","enrolled":329,"outcomes":[]},"route":"/trials/nct05094336/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}